Healthcare
NovoCure Limited(NVCR)
Live Price
Offline$14.28
-20.00% today
1Y Change
-17.60%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.89B
- Revenue Growth
- +8.3%
- EPS Growth
- +21.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NovoCure Limited (NVCR) is a Healthcare stock with a market cap of $1.89B and listed on NASDAQ. The stock last traded around $14.28 and down 17.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +21.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS +21.8%, free cash flow -9.3% with operating margin -27.2% and ROIC -31.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Stock Foundry combines NVCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.3% vs +7.6% peer median
Operating Margin
Below sector median
-27.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.3% and EPS at +21.8%, with operating margin around -27.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +9.3% | +10.7% | +12.0% |
2026 Feb 26, 2026 | +46.3% | -0.6% | +3.5% | -14.5% |
2025 Oct 30, 2025 | +21.4% | -0.1% | -12.1% | -0.1% |
Benchmark Edge
NVCR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVCR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVCR Max Drawdown
-45.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVCR and SPY.
Company Overview
NovoCure Limited
NASDAQ Global Select
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
- Leadership
- Frank Leonard
- IPO Date
- Oct 1, 2015
- Employees
- 1.5k
- Street Address
- No. 4 The Forum
- Mailing
- Saint Helier, JE2 4UF
- Region
- Saint Helier, JE
- Reporting Currency
- USD
- Investor Line
- 44 15 3475 6700
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.8
- Price/Book
- 5.7
Growth
- Revenue
- +8.3%
- EPS
- +21.8%
- Free Cash Flow
- -9.3%
Profitability
- Gross Margin
- 75.2%
- Operating Margin
- -27.2%
- Net Margin
- -25.7%
- ROE
- -50.8%
- ROIC
- -31.8%
Balance Sheet
- Debt/Equity
- 0.71
- Current Ratio
- 2.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.